Stockscreener 앱 받기
7.88
5.40%
-0.45
전일 마감가:
$8.33
열려 있는:
$8.4
하루 거래량:
404.26K
Relative Volume:
0.30
시가총액:
$62.69M
수익:
$49.09M
순이익/손실:
$-52.15M
주가수익비율:
-12.12
EPS:
-0.65
순현금흐름:
$-45.93M
1주 성능:
+44.32%
1개월 성능:
-0.25%
6개월 성능:
+28.55%
1년 성능:
-65.44%
1일 변동 폭
$7.77
$8.71
1주일 범위
$6.9401
$10.00
52주 변동 폭
$3.436
$23.56
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
BDSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
7.88 | 66.27M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump - Sahm
BDSX Stock Price, Forecast & Analysis | BIODESIX INC (NASDAQ:BDSX) - Chartmill
Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability - Investing.com Nigeria
Quarterly Trades: Will Biodesix Inc stock rally after Fed decisions2025 Market Overview & Growth Focused Entry Point Reports - Bộ Nội Vụ
Biodesix: Strengthening Fundamentals, Emerging Profitability, and Strategic Growth Support Buy Rating and $20 Price Target - TipRanks
Biodesix: Strong Operational Momentum but Ongoing Capital Concerns Justify Hold Rating - TipRanks
Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
Biodesix sees stock soar after surpassing sales guidance - BizWest
BDSX Faces Financial Hurdles as Stock Volatility Heightens - StocksToTrade
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
BPASBiodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability - FinancialContent
BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? - Asianet Newsable
Biodesix Stock Rebounds on Strategic Plans for Market Expansion - timothysykes.com
This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why - Stocktwits
Biodesix (BDSX) Surges 41% on Strong Preliminary Q4 and FY Resul - GuruFocus
Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results - Nasdaq
Biodesix skyrockets 43%, expects FY revenue to beat guidance - MSN
Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance - Investing.com India
Biodesix (BDSX) Surpasses 2025 Revenue Expectations with Strong Q4 Performance - GuruFocus
Biodesix, Inc. Reports Estimated Q4 2025 Revenue of $28.8 Million, Achieving 41% Growth and Full-Year Revenue of $88.5 Million, Up 24% - Quiver Quantitative
Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics - TradingView — Track All Markets
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) - Bluefield Daily Telegraph
Biodesix, Inc. Provides Earnings Guidance for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade - MSN
Is Biodesix Inc. stock affected by interest rate hikesWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
What dividend safety score for Biodesix Inc. stockDurability and Wear Notes & HOKA model picks for your routine - ulpravda.ru
Will Biodesix Inc. stock split again soonTreasury Yields & Capital Efficiency Focused Ideas - Улправда
How geopolitical tensions affect Biodesix Inc. stock2025 Momentum Check & Fast Gaining Stock Reports - Улправда
Will Biodesix Inc. stock benefit from automationMarket Risk Report & Fast Exit/Entry Strategy Plans - Улправда
BDSX stock touches 52-week low at $1 amid market challenges - MSN
Fundamentals Check: Why analysts recommend Modine Manufacturing Company MMF stockJuly 2025 Market Mood & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut - MSN
Biodesix CFO sells $22,794 in stock - MSN
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test - MSN
Biodesix, Inc. at Risk: How a Federal Shutdown Could Disrupt Revenue and Growth - MSN
Options Flow: What dividend safety score for Biodesix Inc stock2025 Top Decliners & Low Risk High Win Rate Picks - moha.gov.vn
Analyst Calls: Why analysts upgrade Biodesix Inc stock2025 Price Action Summary & Growth Focused Entry Reports - moha.gov.vn
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Q4 2024 Earnings Call Transcript - MSN
Is Biodesix Inc. stock attractive for retirement portfoliosGap Down & Safe Capital Growth Stock Tips - Улправда
Why Biodesix Inc. stock is considered a top pick2025 Valuation Update & Precise Trade Entry Recommendations - DonanımHaber
Price Action: Can Biodesix Inc. stock continue upward trendEarnings Recap Summary & AI Enhanced Trading Signals - Улправда
Why retail investors favor Biodesix Inc. stockTrade Performance Summary & Step-by-Step Swing Trade Plans - DonanımHaber
Will Biodesix Inc. stock attract ESG investors2025 Major Catalysts & Fast Moving Trade Plans - DonanımHaber
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오데식스 주식 (BDSX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pestano Gary Anthony | Chief Development Officer |
Nov 10 '25 |
Sale |
7.62 |
23 |
175 |
7,939 |
| O'Kane Kieran | Chief Commercial Officer |
Nov 10 '25 |
Sale |
7.62 |
25 |
190 |
7,362 |
| Hutton Scott | President & CEO |
Nov 10 '25 |
Sale |
7.62 |
189 |
1,440 |
37,311 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Nov 10 '25 |
Sale |
7.62 |
50 |
381 |
13,147 |
| SCHULER JACK W | Director |
Sep 19 '25 |
Buy |
7.04 |
142,045 |
999,997 |
1,380,745 |
| SCHULER JACK W | Director |
Sep 17 '25 |
Buy |
6.04 |
15,317 |
92,571 |
1,235,644 |
| SCHULER JACK W | Director |
Sep 18 '25 |
Buy |
6.17 |
3,056 |
18,854 |
1,238,700 |
| SCHULER JACK W | Director |
Aug 29 '25 |
Buy |
0.43 |
3,488,372 |
1,500,000 |
24,406,546 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Aug 13 '25 |
Sale |
0.42 |
988 |
411 |
250,794 |
| Hutton Scott | President & CEO |
Aug 13 '25 |
Sale |
0.42 |
3,772 |
1,570 |
728,824 |
2.51%
0.74%
자본화:
|
볼륨(24시간):